Laboratory Corporation of Amerc Holdings (N:LH)
Business Focus: Healthcare Facilities & Services
| Sector: Healthcare | Industry: Healthcare Facilities & Services |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 358 S MAIN ST BURLINGTON NC 27215-5837 |
| Tel: | 1-336-4365076 |
| Website: | https://www.labcorp.com |
| IR: | See website |
| Key People | ||
| Adam H. Schechter Chairman of the Board, President, Chief Executive Officer | Peter J. Wilkinson Senior Vice President, Chief Accounting Officer | Glenn Andrew Eisenberg Chief Financial Officer, Executive Vice President |
| Thomas H. Pike President, Chief Executive Officer - Clinical Development Business Unit | Mark S. Schroeder Executive Vice President, President Diagnostics and Chief Operations Officer | Judith C. Seltz Chief Human Resource Officer, Executive Vice President |
| Lance V. Berberian Executive Vice President, Chief Information and Technology Officer | Amy B. Summy Executive Vice President, Chief Marketing Officer | Brian J. Caveney Executive Vice President, President Early Development and Chief Medical and Scientific Officer | Sandra Dillard van Der Vaart Executive Vice President, Chief Legal Officer, Chief Compliance Officer, Corporate Secretary |
| Business Overview |
| Laboratory Corporation of America Holdings provides comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. By leveraging its unparalleled diagnostics and drug development capabilities, the Company provides insights and accelerates innovations to improve health and improve lives. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company serves clients in more than 100 countries. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Laboratory Corporation of Amerc Holdings revenues increased 3% to $12.16B. Net income before extraordinary items decreased 62% to $379.2M. Revenues reflect DX segment increase of 2% to $9.42B, BLS segment increase of 3% to $2.77B. Net income was offset by DX segment income decrease of 21% to $1.59B, General corporate segment loss increase of 29% to $1.26B. |
| Employees: | 67,000 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $22,096M as of Dec 31, 2023 |
| Annual revenue (TTM): | $12,162M as of Dec 31, 2023 |
| EBITDA (TTM): | $1,701M as of Dec 31, 2023 |
| Net annual income (TTM): | $379.20M as of Dec 31, 2023 |
| Free cash flow (TTM): | $620.10M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $4,603M as of Dec 31, 2023 |
| Shares outstanding: | 84,125,885 as of Mar 20, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.